# Nuclide record pembrolizumab (drug). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/drugs/pembrolizumab/>
  a schema:Drug ;
  nuclide:kind "drug" ;
  schema:identifier "pembrolizumab" ;
  schema:name "Pembrolizumab"@en ;
  schema:description "Pembrolizumab is a PD-1 blocking antibody approved in more than 40 settings, from melanoma and lung cancer to the first tumour-agnostic approval for mismatch-repair-deficient tumours in 2017, and before and after surgery in triple-negative breast cancer. A subcutaneous form arrived in 2025, and it is the backbone partner for ADCs and personalised neoantigen vaccines."@en ;
  schema:url <https://nuclide.cc/drugs/pembrolizumab/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Pembrolizumab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q13896859> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Pembrolizumab> ;
  nuclide:status "approved" ;
  nuclide:modality "Monoclonal antibody (anti-PD-1)" ;
  schema:alternateName "Keytruda / Keytruda Qlex (SC)" ;
  nuclide:approval "US 2014: Melanoma (first of >40 indications)", "US 2017: MSI-H/dMMR solid tumours (tumour-agnostic)", "US 2020: Metastatic TNBC, PD-L1 CPS ≥10, with chemotherapy", "US 2021: High-risk early TNBC, neoadjuvant + adjuvant (KEYNOTE-522)", "US 2026: Platinum-resistant PD-L1+ ovarian cancer; adjuvant RCC with belzutifan; with sacituzumab govitecan in 1L TNBC" ;
  nuclide:indications <https://nuclide.cc/indications/hcc/>, <https://nuclide.cc/indications/rcc/> ;
  nuclide:companies <https://nuclide.cc/companies/merck/> .